Maze Therapeutics (MAZE) Current Assets (2024 - 2026)

Maze Therapeutics has reported Current Assets for 3 years, with the latest figure at $379.8 million in Q1 2026.

• Quarterly Current Assets rose 26.72% year-over-year to $379.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $379.8 million (up 26.72% YoY) and the FY2025 annual result came in at $349.7 million, up 73.41% from the prior year.
• Current Assets advanced to $379.8 million in Q1 2026 per MAZE's latest filing, from $349.7 million in the prior quarter.
• Over five years, Current Assets peaked at $391.3 million in Q3 2025 and troughed at $201.7 million in Q4 2024.
• A 3-year average of $315.6 million and a median of $324.7 million in 2025 frame the typical range for Current Assets.
• The sharpest annual moves came in 2025 and 2026: Current Assets surged 73.41% in 2025, then advanced 26.72% in 2026.
• Over 3 years, Current Assets stood at $201.7 million in 2024, then soared by 73.41% to $349.7 million in 2025, then rose by 8.6% to $379.8 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $379.8 million, $349.7 million, and $391.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.